Publications by authors named "Maria L Aguirre Azpurua"
Article Synopsis
- ctDNA analysis offers a minimally invasive method for treatment decision-making and monitoring cancer, particularly in patients with advanced-stage non-small cell lung cancer (NSCLC).
- In a study of 72 patients, the UltraSEEK Lung Panel demonstrated a high detection rate (over 90%) for tumor-specific mutations in circulating cell-free DNA (ccfDNA), showing good accuracy compared to droplet digital PCR and traditional tumor tissue testing.
- A significant decrease in ctDNA levels shortly after treatment initiation was linked to longer progression-free survival (PFS) and overall survival (OS), indicating that ccfDNA can effectively track treatment response in NSCLC patients.
Immunotherapy for metastasized non-small-cell lung cancer (NSCLC) can show long-lasting clinical responses. Selection of patients based on programmed death-ligand 1 (PD-L1) expression shows limited predictive value for durable clinical benefit (DCB). We investigated whether early treatment effects as measured by a change in circulating tumor DNA (ctDNA) level is a proxy of early tumor response to immunotherapy according to response evaluation criteria in solid tumors v1.
View Article and Find Full Text PDF